Curative-prophylactic balsam

FIELD: pharmaceutics.

SUBSTANCE: the present innovation deals with enhancing circulation and trophicoregenerative processes. The suggested curative-prophylactic balsam includes fresh-water sulfide-free average-ash sapropel mud of Kirek Lake, turpentine oil (oleoresin turpentine), peroxide, anionic SAS, starch taken at a certain quantitative ratio. The suggested balsam enables to efficiently enhance circulation and trophicoregenerative processes.

EFFECT: higher efficiency of application.

3 ex, 1 tbl

 

The invention relates to medicine, namely to the means of treatment and prevention in surgery, angiology (pathology of arteries, veins, lymph vessels, including complicated by trophic ulcers)in the treatment and prevention of frostbite, trauma (post-traumatic hematomas, contusions, the effects of dislocations); endocrinology complications of diabetes angiopathy extremities; in neurology - when discogenic radiculitis, neuralgia, exacerbation of an osteochondrosis of spine, arthrology - by ankylosing spondylitis, arthritis, chronic arthritis type rheumatoid, in andrology - chronic prostatitis. Offers therapeutic and prophylactic balm “polar star”. (The name is patented, as the trademark application No. 2003408979.)

Known drug collection for treatment and prevention of vascular diseases (patent 94037907, class a 61 K 35/78) in the following ratio by mass: chestnut seed - 1; the fruit of the wild rose - 1; peel of citrus - 1; rhizome with roots cyanosis blue - 1; grass Campion Tatar or drooping - 1. Known composition has limited curative properties.

Known healing balm (patent No. 2157176, a 61 K 7/00) in the following ratio, wt.%: linseed oil - 70,0-to 99.00, propolis - the rest.

Known composition also has limited the authorized spectrum of action.

Closest to the invention to the technical essence is the composition of “White turpentine emulsion” Assalamou (“Hydrotherapy” Wtelecom. M.: Medicine, 1986, s-256), containing:

Distilled water - 550 ml,

Salicylic acid and 75 ml

Soap (powdered) children - 30 g

Oil of turpentine (gum turpentine) cleaned - 500g

White turpentine emulsion was used in physiotherapy in aromatic baths for the treatment of angiospazmam of different origin, patients with atherosclerotic occlusion of major arteries, deforming osteoarthrosis, lumbosacral radiculitis, vegetative polyneuropathy and other diseases.

Constraints for broad clinical use turpentine baths are the following reasons:

Because of the strong smell for turpentine baths should separate room spas with adequate ventilation, the reluctance of medical staff to carry out these procedures (including changes in legislation - as disutility). Baths are a load on the body, especially on the cardiovascular system, causing symptoms “victimize” of the myocardium and brain (appearance, increased heart pains, dizziness, headaches). Amplification of this effect largely depends on the temperature and the fact the RA. Methodology procedure: 35-37 degrees C, the duration 10-15 min, with increasing content of White emulsion in water treatment from 15 to 30 to 35 ml per 200 l of water. Turpentine baths should be performed under medical supervision - an extensive list of contraindications:

Ischemic heart disease with symptoms of angina,

Rhythm disorders of the heart,

Heart failure more than 1 degree,

Hypertension the second and third stage,

Chronic nephritis, nephrosis,

Chronic hepatitis, cirrhosis of the liver,

Contraindications to hydrotherapy at all,

The possible development of skin burns are particularly sensitive areas.

To eliminate the above disadvantages of the task was to create balm with high quality while expanding the range of ointments with a broad spectrum of action, and the possibility of its application to a wide range of patients.

The problem is solved, we offer curative and preventive care balm, comprising, by wt.%:

Freshwater basaltina renesola sapropelic mud

lake Kirek 40,

Oil of turpentine (gum turpentine) 35,

Peroxide 5,0,

Anionic surfactants (surfactant) 2

Starch 18

In the manufacture of balm “polar star” uses simple) is the development of these components in the following sequence: native freshwater renesola sapropelic mud lake Kirek (composition see table 1), anionic surfactants, starch, purified turpentine oil, peroxide. The mixture is then thoroughly mixed and poured into containers. The balm is used as a standalone tool externally.

The most common signs of a part of the prototype and the proposed balm is oil of turpentine (turpentine), peeled, which is in the State Pharmacopoeia described as an essential oil obtained by distillation of the oleoresin of pine, which contains pinene, Karen, dipentene, terpineol and other Freely penetrating through the skin (due to lipotropes), turpentine oil selectively stimulates aerobic metabolism and inhibits anaerobic, which enhances the oxidative processes in the body. This property is important for the application of turpentine oil in patients with impaired oxidative processes in the body, particularly in atherosclerosis. In addition, due to the irritating effect of turpentine oil significantly activates the circulation, including capillary, which has a beneficial effect on tissue metabolism, trophic and regeneration of cells.

As the emulsifier in the balm “polar star” is used anionic surfactants (surfactant).

Introduction in the balm of freshwater bisulfide srednepolny sapropelic mud lake Kirek Tomsk region in the Nati the nom form due to its anti-inflammatory, analgesic effect, a positive effect on metabolism in the body, Tropico-regenerative processes.

Turpentine oil enhances the diffusion of substances in the medical sapropelic dirt.

These two components, complementing their pharmacological characteristics, create a unique composition with curative properties of a wide range of actions.

Included in the balm of peroxide helps to enhance the oxidative processes in the body.

Anionic surfactants is suitable for emulsification of the components of balsam, i.e. the education system between nesovmestimymi elements. It consists of salts of fatty acids, edible fats, palm, coconut oil, mink oil, water, sodium chloride, glycerin, antioxidant, titanium dioxide, sodium salt EDTA.

Another one of the components used in the composition of balsam as an auxiliary substance, it is potato starch. It reduces unnecessary irritant effect turpentine oil due to the fact that has a shielding and antipruritic effect on the skin, softens, protects nerves from irritation.

The application of the proposed balm “polar star” allows to obtain unidirectional therapeutic effect and to show the positive properties of each component, consequently the those which expand the range of therapeutic action, to increase therapeutic activity, to reduce undesirable side effects.

Studies have shown that the balm “polar star” has a number of effects that are useful in the treatment of many common diseases, namely: vasodilators, thrombolytic, antiseptic, wound-healing, anti-inflammatory, thermal, keratolytic, anticonvulsant, analgesic, antispasmodic effect, and can be used in conjunction with other means, and for monotherapy. Proposed balm is a highly effective, non-pharmacological tool, easy to use and is available in any health care setting and the home.

The invention is illustrated by the following examples.

Example 1.

Patient S., 49, suffered widespread osteochondrosis of the spine, with a primary lesion of the lumbosacral complicated paramedian hernia L3-L4-L5-S1from 1978. Annually (spring-autumn) in the period of exacerbation disabled by 1.5 months. 23.05.91 urgently operated on for pelvic disorders. Operation interlaminate L3-L4-L5-S1on the left, curettage L4-L5disk drive, revision of adjacent intervals. After the surgery recommended: do not sit, walk with crutches d is 2 months, wearing removable corset, periodic courses resolving therapy, physiotherapy, exercise therapy.

In October 1991 (exacerbation) in patients receiving indomethacin developed peptic ulcer disease duodenal ulcer complicated by bleeding. Hospitalized at the surgical hospital by ambulance. Conducted hemostatic therapy, blood transfusion, antiulcer therapy.

Since 1992, due to increased pain in the spine and the inability to take non-steroidal anti-inflammatory drugs due to their ulcerogenic (ulcerative) of action was to apply the balm "polar star" courses in the spring and autumn period - externally. Since 1992, working without special limitations on physical activity, and for the period from 1992 to 2003 had never been on the sick-list.

Example 2.

Patient E. 33 years, from 1985, is under the supervision of a physician or surgeon, for sickness Reynaud 2-3 tbsp.

Rheovasography from 03.2002, pulse, crownpointe vessels of both forearms, is moderately more than the right. Vascular tone is increased. The slowing of the venous outflow expressed. Pulse blood pressure of both hands sharply reduced (DS). Tonus of vessels of lower extremities elevated. The slowing of the venous outflow expressed. Pulse filling of the vessels of both tibiae moderately reduced (D=S). Tone SOS the funds raised. The slowing of the venous outflow. Pulse blood pressure of both feet significantly reduced (D=S). Electric thermometer (before treatment) stop: base 1 finger - 24.5 degrees C, the base 4 of the finger - 25.3 degrees C.

Purpose: the balm "polar star" - external courses a day in October 2002. Autumn-winter-spring period was uneventful, disappeared chilliness, cyanosis, swelling of the fingers and toes. Increased quality of life. Control electric thermometer, April 2003, feet: base 1 finger - 27.8 degrees With the base 4 of the finger - 28 degrees C.

Other drugs were taken.

Example 3

Patient U., 65 years suffers postthrombotic syndrome of left leg since 1985, the clinical course was complicated by the presence of mycotic eczema left tibia pseudotuberculosis.

Repeatedly treated conservatively in different clinics Tomsk surgical and dermatological profile was observed by the infectious diseases specialist.

In 1996, on the front-side surface in the lower third of the left tibia was formed trophic ulcer with a total area of 23 cm2. Conducted plasmapheresis, rheological drugs, physical treatment. Speakers from local status does not occur, the ulcer remained 7 years.

In December 2002, in consultation revealed: in the middle third of the left tibia above ulcers along the great saphenous vein density is th cord length 14 cm, with symptoms of redness, pastoznost, sharp pain on palpation. In the lower third of the left tibia trophic ulcer with a total area of 23 cm2covered pomegranate scab, hyperemia around the ulcer. Assigned balm "polar star" externally around the ulcer on the leg. Conducted toilet ulcers, ulcer deposited layer indifferent ointment (vaseline medical), bandage.

The plague quickly got rid of scab formed granulation. After 14 days of heavy Vienna was no longer palpable, no pastoznost and edema of the leg. Healing followed by epithelialization and granulation from the bottom of the ulcer.

In February 2003, the ulcer healed completely.

Table No. 1
The main components% crude substance
Water (normal 60-90%)82.5
Organic matter %28,0
Ash content, %61,3
The composition of the ash, %

1. Fe2O3
0,56
2. Al2About30.0
3. SiO20,92
So26,8
5. MDO1,12
6. SO30,13
7. P2About30.11

Of preventive and curative balm, increase blood circulation and Tropicalisation processes, including freshwater bisulfide srednepolny sapropelic mud lake Kirek, oil of turpentine (gum turpentine), peroxide, anionic surfactants, starch, taken in the following ratio, wt.%:

Freshwater basaltina renesola sapropelic mud

lake Kirek 40

Oil of turpentine (gum turpentine) 35

Peroxide 5

Anionic surfactants 2

Starch 18



 

Same patents:

FIELD: medicine.

SUBSTANCE: chitosan oligosaccharides are obtained by enzymatic hydrolysis of 10 % chitosan solution for 30-50 min. Then chitosan and chitosanase are additionally added into solution to produce total chitosan concentration of 10 mass %, and fermentation is carried out up to total time of 20-24 h. In another embodiment beforehand enzymatic hydrolysis of 5 % chitosan solution for 30-50 min is carried out, then chitosan and chitosanase are additionally added into solution to produce total chitosan concentration of 10 mass %, and fermentation is carried out for 30-50 min. After that chitosan and chitosanase are added into solution again to produce total chitosan concentration of 15 mass %, and fermentation is carried out up to total time of 20-24 h. In the third embodiment into aqueous solution containing organic acids simultaneously chitosan in amount of 10-15 mass % and chitosanase are added and fermentation is carried out for 20-24 h. In all variants mixture of acetic and ascorbic acids, acetic acid, mixture of acetic and succinic acids, mixture of ascorbic and succinic acids are used as organic acids. Method of present invention makes it possible to increase target product yield by 2-3 times without losses of characteristics thereof.

EFFECT: method of improved yield; product of high quality.

7 cl, 1 tbl, 8 ex

FIELD: biochemistry.

SUBSTANCE: method relates to new cyclopeptides of general formula cyclo(R1-Arg-Ile-Lys-Pro-His-R2) selected from group containing: P11: cyclo(DPhe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu) (SEQ ID NO:5), P16: cyclo(Arg-Ile-Lys-Pro-His-Gln-Gly (SEQ ID NO:8), P17: cyclo(Pro-Arg-Ile-Lys-Pro-His-Gln-Gly) (SEQ ID NO:9), P19: cyclo(Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu) (SEQ ID NO:10), P20: cyclo(Dphe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly) (SEQ ID NO:11), P23: cyclo(DPhe-Pro-Arg-Ile-Lys-Pro-His-Gln) (SEQ ID NO:13), P24: cyclo(Gly-Arg-Ile-Lys-Pro-His) (SEQ ID NO:25), as well as P11, P20 and P23 with DPhe substituted by DTyr. Cyclopeptides are useful in systems for angiogenesis inhibition. System includes substrate with cyclopeptides attached by organic spacer arm optionally containing group cleavable by any fermentation system.

EFFECT: angiogenesis inhibiting cyclopeptides.

23 cl, 4 dwg, 2 tbl, 2 ex

FIELD: organic chemistry, pharmaceutical composition.

SUBSTANCE: compounds satisfying the formula I 1 are disclosed, wherein each R1 and R2 independently to one another are H, OH, OA or Hal; or R1 and R2 together are -O-CH2-O- or -O-CH2-CH2-O-; R3 and R4 are A-group; X - group monosubstituted with R8, R5 or R7; R5 is linear or branched C1-C10-alkylene, wherein one or two CH2-groups may be substituted with oxygen atom; R7 is phenyl or phenylmethyl; R8 is COOH, COOA, CONH2, CONHA, CON(A)2 or CN; F is C1-C6-alkyl; and Hal is F, Cl, Br, or I, as well as physiologically acceptable salts or solvates thereof. Methods for production of claimed compounds (I) and pharmaceutical composition containing the same also are disclosed. Said compounds and pharmaceutical composition have activity as phosphodiesterase V inhibitors and are useful in treatment of cardiovascular diseases and potency disorders.

EFFECT: pharmaceutically applicable compounds and compositions.

7 cl, 16 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new derivatives of benzene of the formula (I): wherein A represents a group taking among the following groups: -C≡C-, -CH=CH-, -CH2-CH2; n = 1 or 2; X represents hydrogen, chlorine or fluorine atom or methyl or methoxy-group; Y represents hydrogen, chlorine or fluorine atom; R1 represents cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with methyl group, phenyl group monosubstituted or disubstituted with fluorine or chlorine atom or methoxy-group, cycloheptyl, tert.-butyl, dicyclopropylmethyl, 4-tetrahydropyranyl or 1- or 2-adamantyl, or adamantine-2-ol group; or R1 represents phenyl group and in this case X and Y both represents chlorine atom; R2 represents hydrogen atom or (C1-C4)-alkyl group; R3 represents (C5-C7)-cycloalkyl, and salts of these compounds formed by addition of pharmaceutically acceptable acids, and their solvates and hydrates also. Also, invention relates to methods for preparing compounds of the formula (I) and to pharmaceutical composition able to interact with receptors sigma-2 based on these compounds. Invention provides preparing new compounds and medicinal agents based on thereof for treatment of autoimmune states, disturbance on heart contraction frequency and control against proliferation of tumor cells.

EFFECT: improved preparing methods, valuable medicinal properties of compositions.

18 cl, 14 tbl, 78 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with phospholipid complexes of proanthocyanidine A2 and pharmaceutical compositions upon their basis as antiatherosclerotic agents, those for preventing and treating myocardial and cerebral infarction. Phospholipids of the above-mentioned complex should be preferably chosen out of lecithins, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine. The innovation provides the preparation to treat the above-mentioned diseases due to decreasing the quantity and burden of atheromatous plaque, decreased obstruction of carotid arteries and decreased thickness of vascular walls.

EFFECT: higher efficiency of prophylaxis and therapy.

9 cl, 11 dwg, 6 ex, 2 tbl

FIELD: organic chemistry, heterocyclic compounds, purines, medicine.

SUBSTANCE: invention relates to a method for treatment of arrhythmia in mammal. Method involves administration of agonist of adenosine A1-receptors in the therapeutically effective minimal dose of the formula:

wherein R1 represents optionally substituted heterocyclic group. The indicated dose of agonist is in the range from 0.0003 to 0.009 mg/kg. Method shows the enhanced effectiveness and doesn't result to undesirable adverse effects.

EFFECT: improved treatment method, valuable medicinal properties of substances.

11 cl, 1 dwg, 2 ex

FIELD: organic chemistry, medicine, cardiology, pharmacy.

SUBSTANCE: invention relates to a medicinal preparation used in treatment of chronic cardiac insufficiency. The preparation represents 3-methyl-5-[2-(3-tert.-butylamino-2-oxypropoxy)- phenoxymethyl]-1,2,4-oxadoazole hydrochloride. The preparation provides expanding assortment of medicinal agents used in treatment of chronic cardiac insufficiency.

EFFECT: valuable medicinal properties of drug.

5 tbl

FIELD: medicine, cardiology, pharmacy.

SUBSTANCE: invention relates to carvedilol-containing pharmaceutical composition that is used for treatment and/or prophylaxis of hypertension, cardiac insufficiency or stenocardia. The composition comprises carvedilol or its pharmaceutically acceptable salt and one or some adjuvants. Carvedilol is distributed in adjuvants as a molecular dispersion. Adjuvants are not surface-active substance and/or non-ionogenic surface-active substance. The concentration of adjuvants exceeds 5 wt.-%. Also, invention describes a method for preparing the composition and pharmaceutically acceptable solid formulation for oral administration. Compositions of the present invention provide the enhancing solubility of carvedilol and level of its absorption in lower regions of intestine.

EFFECT: improved and valuable pharmaceutical properties of composition.

17 cl, 9 ex

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to a new biologically active compound representing maleic acid 4-methyl-2-pyridylamide of the formula: . Compound is synthesized by interaction of 4-methyl-2-aminopyridine with maleic anhydride. Compound represents white crystalline substance soluble in water, dimethylformamide (DMFA) and dimethylsulfoxide (DMSO) with value Tm = 146oC. Compound elicits the hypertensive activity elevating arterial pressure value in narcotized cats after intravenous administration in the dose 5 mg/kg (about 0.1 LD50) by 60.4 ± 8.23 mm mercury column reliably and acts for 90 min. Value LD50 in intravenous administration to white mice is 44.7 (39-50) mg/kg.

EFFECT: valuable medicinal properties of compound.

1 cl, 1 tbl, 1 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: organic chemistry and pharmaceutical compositions.

SUBSTANCE: invention relates to new 3-(5)-heteroaryl-substituted pyrazoles of formula I , tautomers or pharmaceutically acceptable salt of compounds and tautomers. In formula R1 is hydride, piperidinyl substituted with methyl, lower alkyl optionally substituted with halogen, hydroxyl, lower alkylanimo or morpholino; R2 is hydride, lower alkyl, amino, aminocarbonylamino, lower alkylaminocarbonylamino, lower alkylsulfonylamino, aminosulfonylamino, lower alkylaminosulfonylamino; Ar1 is phenyl optionally substituted with one or more independently selected halogen; HetAr2 is pyridinyl with the proviso that R2 is not amino or n-propyl when HetAr2 is pyridinyl; and HetAr2 is not 2-pyriridinyl when R2 is hydrogen or lower alkyl. Compounds of formula I have kinase p38 inhibitor activity and are useful in pharmaceutical compositions for treatment of various diseases.

EFFECT: new effective kinase p38 inhibitors.

23 cl, 6 dwg, 1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with cyclosporin-containing and practically oil-free compositions being of immunosuppressive action. The composition contains a hydrophilic surface-active substance, a lipophilic component, a lipophilic surface-active substance and ethanol. As a hydrophilic surface-active substance this composition contains ether of fatty acid and polyoxyethylene sorbitane and product of either natural or hydrogenised castor oil and ethylenoxide; as a lipophilic component and lipophilic surface-active substance it contains ether of fatty acid and sorbitane. The suggested composition has been designed as a gelatinous capsule with solid covering. The present innovation solves the problem dealing with stability of galena compositions with cyclosporin: at treating with water the composition develops practically stable microemulsion.

EFFECT: higher efficiency of application.

11 cl, 2 ex

FIELD: organic chemistry, steroids, medicine, pharmacy.

SUBSTANCE: invention relates to 3-methylene-steroid derivative of the general formula (1):

wherein R1 means hydrogen atom (H), or in common with R3 it forms β-epoxide; or R1 is absent in the presence of 5-10-double bond; R2 means (C1-C5)-alkyl; R3 means βH, βCH3 or in common with R1 it forms β-epoxide; either R3 is absent in the presence of 5-10-double bond; R4 means hydrogen atom, lower alkyl; Y represents [H, H], [OH, H], [OH, (C2-C5)-alkenyl], [OH, (C2-C5)-alkynyl] or (C1-C6)-alkylidene, or =NOR5 wherein R5 means hydrogen atom (H), lower alkyl; dotted lines represent optional double bond. Compound can relate also to its prodrug used for treatment of arthritis and/or autoimmune diseases.

EFFECT: valuable medicinal properties of compounds, improved method for treatment.

38 cl, 1 tbl, 18 ex

FIELD: experimental medicine.

SUBSTANCE: on should introduce solution into fracture area at the following ratio of ingredients, g/l: 1-hydroxyethylidenediphosphonic acid 1.80 - 2.06, water-free calcium chloride 1.44 - 2.22, gadolinium (III) nitrate hexahydrate 0.30 - 0.40, dysprosium (III) chloride hexahydrate 0.038 - 0.076, moreover, solution's pH corresponds to 7.3 - 7.8. The present innovation enables to shorten the process of bony tissue regeneration in the site of its lesion or defect and, also, shorten the period for restoring normal physiological function of traumatized bone.

EFFECT: higher efficiency of regeneration.

22 ex, 1 tbl

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: organic synthesis.

SUBSTANCE: invention provides compounds of general formula I:

in which R1 represents H, halogen, OCH3, or OH; R2 represents (a) -X-(CH2)n-CH2-N(R4)R5, where (i) X represents NH or S; n is integer from 1 to 4; R4 and R5, the same or different, represent C1-C4-alkyl, H, -CH2C≡CH, or -CH2CH2OH; or R4 and R5, together, form nitrogen-containing five- or six-membered cycle or heteroaromatic cycle; or where (ii) X represents O; n is integer from 1 to 4; one of R4 and R5 is CH2C≡CH, or -CH2CH2OH and the other H or C1-C4-alkyl; or R4 and R5, together, form imidazole cycle or nitrogen-containing six-membered cycle or heteroaromatic cycle; or R2 represents (b) -Y-(CH2)nCH2-O-R5, where (i) Y represents O; n is integer from 1 to 4; and R6 represents -CH2CH2OH or -CH2CH2Cl; or where (ii) Y represents NH or S; n is integer from 1 to 4; and R6 represents H, -CH2CH2OH, or -CH2CH2Cl; or R2 represents (c) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, or 2,2-diethyl-2-hydroxy-ethoxy; R3 represents H. halogen, OH, or -OCH3. Claimed compounds are novel selective estrogen receptor modulators. Invention also discloses pharmaceutical composition and a method for production of tissue-specific estrogenic and/or antiestrogenic effect in patient, for whom indicated effect is required.

EFFECT: increased choice of estrogen receptor modulators.

19 cl, 7 tbl, 11 ex

FIELD: medicine.

SUBSTANCE: method involves administering selective modulator of steroid sex hormones being in particular compounds of general formula(I) and some quantity of steroid sex hormones precursor selected from a group composed from dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-en-3β,17β-diol and compounds in vivo transformable into one of cited precursors. Bisphosphonates combined with selective estrogen receptor modulators and/or steroid sex hormones precursor are additionally introduced for medically treating and/or inhibiting osteoporosis progress.

EFFECT: enhanced effectiveness of treatment; excluded adverse side effects.

41 cl, 13 dwg, 4 tbl

FIELD: veterinary science.

SUBSTANCE: the suggested method should be implemented under conditions of experimental modeling dystrophic process due to intramuscular injection of glucosamine hydrochloride at the dosage of 15-25 mg/kg once or twice weekly for 1 mo. The method provides good effect in treating a lesion induced in the course of an experiment due to matching adequate dosages and a certain mode of injecting chondroprotector in animals.

EFFECT: higher efficiency of correction.

6 dwg

FIELD: veterinary science.

SUBSTANCE: the suggested method should be performed under conditions of experimental modeling dystrophic process due to intraosseous introduction of glucosamine hydrochloride at the dosage of 15-25 mg/kg 1-2 times weekly during a month. The method provides high local concentrations of medicinal preparation, at its steady entering the circulation by leaving aside hepatic barrier and, as a result, optimization of chondroprotector action of glucosamine hydrochloride and better treatment of articular alterations induced in the course of an experiment in animals.

EFFECT: higher efficiency of correction.

8 dwg, 1 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition for oral administration in treatment or prophylaxis of obesity or hyperlipidemia. The composition comprises orlistat and at least one ester of fatty acids and polyols. Melting point of fatty acid ester exceeds the body temperature and polyol is taken among group including glycerol, sugars, derivatives of sugars and their mixtures. Also, invention relates to a method for preparing above described composition and to a method for treatment or prophylaxis of obesity. Invention enhances effectiveness and activity of orlistat by reducing variability of effectiveness and/or activity of orlistat between patients and frequency and severity of adverse effects.

EFFECT: improved and valuable pharmaceutical properties of compositions.

24 cl, 1 tbl, 10 ex

Up!